Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
$0.00
$0.00
$0.00
N/AN/AN/A11,500 shs
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$157.12
-0.2%
$140.70
$91.86
$254.15
$7.72B1.491.03 million shs247,085 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
0.00%0.00%0.00%0.00%0.00%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.00%+4.81%+8.56%+17.28%-21.31%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
4.0649 of 5 stars
2.12.00.04.72.42.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
0.00
N/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.19
Hold$171.859.37% Upside

Current Analyst Ratings Breakdown

Latest OBJ, BUX, BD1, and CRL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/23/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$188.00 ➝ $182.00
5/14/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
5/14/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$179.00
5/8/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$145.00 ➝ $155.00
5/8/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$118.00 ➝ $140.00
5/8/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeIn-Line ➝ Outperform$170.00
4/10/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$160.00 ➝ $145.00
4/9/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$175.00 ➝ $155.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.05B1.91$21.70 per share7.24$67.80 per share2.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$22.20M-$0.65N/A14.285.32-0.66%15.19%6.93%8/6/2025 (Estimated)

Latest OBJ, BUX, BD1, and CRL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.06$2.34+$0.28$0.50$942.34 million$984.17 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.78
1.43
1.16

Institutional Ownership

CompanyInstitutional Ownership
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
98.91%

Insider Ownership

CompanyInsider Ownership
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
1.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biomark Diagnostics Inc. stock logo
BUX
Biomark Diagnostics
N/AN/AN/ANot Optionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
20,10049.12 million48.48 millionOptionable

Recent News About These Companies

3 Reasons to Sell CRL and 1 Stock to Buy Instead

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Biomark Diagnostics stock logo

Biomark Diagnostics CNSX:BUX

BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.

Charles River Laboratories International stock logo

Charles River Laboratories International NYSE:CRL

$157.12 -0.37 (-0.23%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$157.12 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.